OVERALL PROGRAMME REVIEW

GLOBAL STRATEGY AND PLAN OF ACTION ON PUBLIC HEALTH, INNOVATION AND INTELLECTUAL PROPERTY (GSPA-PHI)

OPEN SESSION

GSPA-PHI Background

- The GSPA-PHI has been developed through an inter-governmental working group and endorsed at the 61st WHA in 2008 - (WHA 61.12).
- The aim of the GSPA-PHI is to promote new thinking on innovation and access to medicines
- and to secure an enhanced and sustainable basis/framework for needs-driven essential health research and development, relevant to diseases that disproportionately affect developing countries.
- GSPA-PHI timeframe has been extended to 2022

GSPA-PHI: 8 Elements

1-Prioritizing research & development needs
2-Promoting research and development
3-Building and improving innovative capacity
4-Transfer of technology
5-Application and management of IP to contribute to innovation and promote Public Health
6-Improving delivery and access
7-Promoting sustainable financing mechanisms
8-Establishing monitoring and reporting systems

GSPA –PHI Evaluation and Review

- WHA 68.18, requested WHO DG to initiate a comprehensive evaluation of the implementation of GSPA-PHI - documenting achievements, challenges, recommendations for addressing gaps – Evaluation was presented at 70th WHA

- Member States requested WHO DG to carry out an overall programme review (WHA68.18) - the mission of the Review is to look forward, in the current broad policy context and recommend improved policies and actions for the next stages of GSPA-PHI

- A panel was established with 18 experts with diverse and complementary expertise covering the 8 elements of the GSPA-PHI, taking into account gender balance and equal regional representation; endorsed by 140th EB Officers, in January 2017

Terms of reference of the Review

- (a) assess the continued relevance of the aim and objectives and the eight elements of the GSPA-PHI;
- (b) consider the evaluation of the implementation so far and its key barriers;
- (c) review achievements, good practices, success factors, opportunities, gaps, weaknesses, unsuccessful efforts, remaining challenges, and value for money;
- (d) invite appropriate input and comment from WIPO, WTO, and UNCTAD and other relevant intergovernmental organizations;
- (e) recommend a way forward, including elements/actions to be added, enhanced or concluded in the implementation until 2022
- (f) submit a final report to the Health Assembly in 2018, including the assessment of the GSPA-PHI and recommendations on the way forward

Proposed Method of Work

- Face to face meetings of the Review panel held in March, June and September at WHO headquarters.
- A half-day open session organized at each panel meeting to allow input from Member States, United Nations specialized agencies and all categories of non-State actors in line with FENSA
- The GSPA-PHI Review secretariat will make all necessary arrangements to ensure that the review is conducted at “arm’s length” and with full attention to avoid conflicts of interests.

- The review shall be carried out in accordance with principles such as:
  - independence,
  - impartiality,
  - inclusiveness, and
  - transparency.

Proposed Method of work

- Additional information will be gathered from Member States and stakeholders through web based questionnaires and phone or face to face interviews.
- Input will also be sought from WHO Regional Offices and other regional institutions and communities.
- Other evidence in the form of reports or peer reviewed publications will also be used to inform the review.
- The panel will commission extra research, through the GSPA-PHI secretariat, on specific subjects.

Review of progress

- First review panel meeting, 23 and 24 March 2017 to define its method of work, identify deliverables and timelines, as well as the structure of the review report.
- 3 sub-groups established and outlines of first 3 chapters drafted

  Chapter 1: Setting the scene, overview of the situation of R&D and access to medicines;
  Chapter 2: Mapping of current activities related to R&D and access to medicines;
  Chapter 3: Lessons learnt and implementation of the recommendations of the GSPA evaluation report.
- Sub-group calls held to monitor drafting of chapters & to ensure involvement of group members
- Chapters 1 & 3 drafted and commissioning of research work for Chapter 2
- On-line survey questionnaire developed to consult with Member States and stakeholders from private sector, inter and non-governmental organizations, academics etc. on the relevance of the GSPA-PHI elements and sub-elements & way forward.

Objectives of the second experts panel meeting 14 & 15 June

- Presentation and review of Chapter 1 and 3 and of data for Chapter 2 in plenary and in group work
- Identify gaps and additional work and research needed
- Review of Member States and stakeholders surveys results
- Develop outline for the final chapter (the way forward and implementation plan)
- Timelines and objectives of next meeting and expected deliverables

Next Steps and Timelines

- Drafting of the final chapter (June - July)
- Finalize all chapters and transmission of draft report to the experts panel for comments (first week of September)
- Editing of report (1st week of September)
- Third and final meeting, endorsement of report by panel, (14-15 September)
- Submission of report to DG and to translation (2 October)
- The final report will be presented to the Seventy-first World Health Assembly in 2018 (May 2018) through the Executive Board at its 142nd session (January 2018).

Questions for the open session

- In the context of the GSPA-PHI, how can R&D for medicines be improved? (please feel free to comment on any aspect of R&D for medicines, from issues relating to intellectual property to possible funding models)

- In the context of the GSPA-PHI, how can access to medicines be improved?

- Are there any issues not addressed by the GSPA-PHI and that you consider relevant to R&D and access to medicines? Are there elements, sub-elements or actions that you would drop ?